|Mr. Joseph P. Hagan||Pres, CEO & Director||623.86k||N/A||48|
|Dr. Timothy Michael Wright M.D., Ph.D.||Chief R&D Officer||252.75k||N/A||61|
|Mr. Daniel R. Chevallard CPA||Chief Financial Officer||N/A||N/A||N/A|
|Ms. Allison Wey||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Christopher Aker J.D.||VP of Legal Affairs & Corp. Sec.||N/A||N/A||N/A|
Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. Its clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease. The company has strategic alliance with AstraZeneca AB and Sanofi to discover, develop, and commercialize microRNA therapeutics; and Biogen Inc. on microRNA biomarkers for multiple sclerosis, as well as a clinical trial collaboration agreement with GSK LLC. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Regulus Therapeutics Inc.’s ISS Governance QualityScore as of July 1, 2017 is 8. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 5; Compensation: 10.